MMWR Morb Mortal Wkly Rep. 2007 Apr 6;56(13):304-7.
Before the introduction of measles-containing vaccine (MCV), measles was endemic in South Korea. MCV became available in South Korea in 1965, and measles, mumps, and rubella (MMR) vaccine was added to the country's national immunization program in 1983, with 1 dose administered at age 9-15 months. In 1997, a second dose of MCV (MCV2) was added to the schedule; recommended ages for administration of MCV1 and MCV2 were 12-15 months and 4-6 years, respectively. However, with insufficient policies and programs in place to promote 2-dose coverage, this 1997 recommendation achieved limited coverage with 2 doses of MCV. In a 2000 seroepidemiologic study among children aged 7-9 years who had been eligible for vaccination since 1997, only 39% had received MCV2 (Korea Centers for Disease Control and Prevention [KCDC], unpublished data, 2001). During 2000-2001, South Korea experienced a measles epidemic that affected tens of thousands of children. In response, in 2001, South Korea announced a 5-year National Measles Elimination Plan. This report describes the activities and summarizes the results of that plan, which enabled South Korea to announce in late 2006 that interruption of indigenous measles transmission had been achieved, making South Korea the first country in the World Health Organization's (WHO) Western Pacific Region declare measles eliminated.
在含麻疹疫苗（MCV）引入之前，麻疹在韩国呈地方性流行。MCV于1965年在韩国上市，1983年麻疹、腮腺炎和风疹（MMR）疫苗被纳入该国国家免疫规划，在9至15月龄接种1剂。1997年，免疫程序中增加了第2剂MCV（MCV2）；MCV1和MCV2的推荐接种年龄分别为12至15月龄和4至6岁。然而，由于缺乏足够的政策和项目来促进2剂次接种覆盖率，1997年的这一推荐实现的2剂次MCV覆盖率有限。在一项2000年针对自1997年起符合接种条件的7至9岁儿童的血清流行病学研究中，只有39%的儿童接种了MCV2（韩国疾病控制与预防中心[KCDC]，未发表数据，2001年）。在2000 - 2001年期间，韩国经历了一场影响数万名儿童的麻疹疫情。作为回应，韩国在2001年宣布了一项为期5年的国家麻疹消除计划。本报告描述了该计划的活动并总结了其结果，该计划使韩国能够在2006年末宣布实现了本土麻疹传播的阻断，使韩国成为世界卫生组织（WHO）西太平洋区域首个宣布消除麻疹的国家。
